Samsung Electronics Co., Ltd.

Yonsei University

Georgetown University

Samsung Life Public Welfare Foundation

Dongjin Semichem Co., Ltd.

Samsung Life Welfare Foundation

Kyung Ah Kim

Ji Min Lee

Bo Gyou Kim

Yun Ju Jeong

Saet Byoul Lee

Jae Young Choi

Seung Hyun Lee

Yun Jeong Song

Young Mi Oh

Ho Yeong Song

Youngwook Kim

Kwang Ho Cheong

Soo Yeon Jung

Seung Ja Oh

Seon Hui Shim

Keunchil Park

Seungja Oh

Jeong Min Kim

Kwang Ho Lee

Jang Hui Kim

Seong Gyu Kwon

Chang Hun Kwak

Kyung Eun Kim

Mi Young Cho

Hyo Seon Lee

Louis M Weiner

Yoon Ho Kang

Powei Lin

Jae Woong Hwang

Won Suk Lee

Eunjin Lee

Tae Jin Ahn

Shangzi Wang

Jae Hyun Choi

Geun Woong Kim

Byoung Joo Kim

Jimin Lee

Hyun Il Cho

Hye Won Park

Yumi Lee

Chan Seok Park

Woo Sun Kwon

Chungho Kim

Gil Lae Kim

Yoon Aa Choi

Sun Young Rha

A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.

Biomarker PNCK for predicting effect of a dual-targeting agent

A method for predicting and/or monitoring the efficacy of a c-Met inhibitor using a biomarker; a method for selecting a subject suitable for the application of a c-Met inhibitor using a biomarker; and a method for preventing and/or treating cancer comprising administering a c-Met inhibitor to the selected subject.

Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF

A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.

Combination therapy using P53 activator and c-Met inhibitor

A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, 'c-Met inhibitor') and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.

Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers

A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

Biomarker Hsp90 for predicting effect of a c-Met inhibitor

A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, 'c-Met/EGFR dual inhibitor') and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.

Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor

Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases

Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.

PDGF as a biomarker for predicting resistance or effect of c-Met targeting drugs

A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.

Biomarker TFF1 for predicting effect of C-MET inhibitor

An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.

Anti-c-Met/anti-Ang2 bispecific antibody

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Method of combination therapy using an anti-C-Met antibody

There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment

A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Method of combination therapy using an EGFR antagonist and anti-c-Met antibody

A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Combination therapy for the treatment of cancer using an anti-C-met antibody

A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Combination therapy using anti-C-met antibody and anti-ang-2 antibody

Growing community of inventors

Seongnam-si, South Korea

Kyung Ah Kim